Real-World Studies
Cohort links NATALEE and monarchE eligibility to poorer breast cancer survival
Voutilainen et alThe oncologist

In a retrospective, population-based cohort study conducted in the Hospital District of Helsinki and Uusimaa, Finland, researchers evaluated the real-world prevalence and prognostic implications of clinical trial eligibility criteria for adjuvant CDK4/6 inhibitors. The cohort included 8,911 patients diagnosed with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer between January 2014 and June 2023, followed for a median duration of 5.2 years.
Overall, 40.4% of patients met the NATALEE trial eligibility criteria and 15.0% met the monarchE trial eligibility criteria. Patients eligible under either trial framework were generally younger and presented with higher-grade tumors and elevated proliferation rates compared to ineligible counterparts.
Across evaluated survival endpoints, five-year outcomes were consistently poorer in trial-eligible patients compared with ineligible patients. For NATALEE-eligible versus ineligible patients, five-year invasive disease-free survival (iDFS) was 82.5% versus 89.6%, distant disease-free survival (DDFS) was 88.3% versus 94.5%, and overall survival (OS) was 90.9% versus 95.6%. For monarchE-eligible versus ineligible patients, five-year iDFS was 76.8% versus 88.4%, DDFS was 82.3% versus 93.8%, and OS was 86.8% versus 94.9%. Metastatic progression occurred three- to six-fold more frequently in eligible patients, and multivariable modeling identified both NATALEE and monarchE eligibility as associated with distant metastasis and mortality. The authors noted that these real-world outcomes align with control-arm observations from phase III trials and support risk-adapted adjuvant strategies incorporating CDK4/6 inhibitors into clinical management.
Key Takeaways
- Among 8,911 patients with HR+/HER2- early breast cancer, 40.4% met NATALEE and 15.0% met monarchE eligibility criteria, with eligible patients experiencing a three- to six-fold higher rate of metastatic progression compared to ineligible individuals.
- Five-year outcomes were lower among trial-eligible versus ineligible patients for NATALEE (iDFS 82.5% vs 89.6%, DDFS 88.3% vs 94.5%, OS 90.9% vs 95.6%) and monarchE (iDFS 76.8% vs 88.4%, DDFS 82.3% vs 93.8%, OS 86.8% vs 94.9%).
- In multivariable models, meeting either NATALEE or monarchE trial eligibility criteria was independently associated with distant metastasis and mortality over a median follow-up of 5.2 years.
Read the original sourceThe oncologist
